Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC

Phase 2

Recruiting

Conditions: Fruquintinib
Raltitrexed
S-1

Interventions: Drug: Fruquintinib
Drug: S-1
Drug: raltitrexed

First Posted Date: 2024-05-23

Last Posted Date: 2024-05-23

Lead Sponsor: West China Hospital

Target Recruit Count: 66

Registration Number: NCT06427005

Locations: 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Early Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Inulin

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 30

Registration Number: NCT06347198

Locations: 🇨🇳
Min Jin, Wuhan, Hubei, China

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Phase 2

Not yet recruiting

Conditions: Colo-rectal Cancer

Interventions: Drug: Tislelizumab
Drug: Fruquintinib
Drug: Chidamide

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 17

Registration Number: NCT06218888

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Completed

Conditions: Colorectal Cancer
Refractory Colorectal Cancer
Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-11

Lead Sponsor: Fudan University

Target Recruit Count: 520

Registration Number: NCT06202417

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Completed

Conditions: Bone Sarcoma
Soft Tissue Sarcoma
Refractory Tumor

Interventions: Drug: Fruquintinib

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-17

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 124

Registration Number: NCT06202599

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Cadonilimab
Radiation: SBRT

First Posted Date: 2023-12-13

Last Posted Date: 2023-12-21

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT06168786

Locations: 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Phase 4

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2023-11-07

Last Posted Date: 2023-11-07

Lead Sponsor: The First Affiliated Hospital of Nanchang University

Target Recruit Count: 30

Registration Number: NCT06118762

Locations: 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Second Affiliated Hospital of Nanchang University

Target Recruit Count: 45

Registration Number: NCT06094868

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Completed

Conditions: Metastatic Colorectal Adenocarcinoma

Interventions: Drug: Trifluridine/Tipiracil
Drug: Fruquintinib
Drug: PD-1 inhibitors
Drug: Bevacizumab

First Posted Date: 2023-09-11

Last Posted Date: 2023-09-11

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 106

Registration Number: NCT06031376

Locations: 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Fruquintinib

First Posted Date: 2023-08-31

Last Posted Date: 2023-08-31

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 64

Registration Number: NCT06018714

Locations: 🇨🇳
Colorectal Department,SunYat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy